STA
PCRX icon

Summit Trail Advisors’s Pacira BioSciences PCRX Stock Holding History

Summit Trail Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-15,103
Closed -$400K – 620
2018
Q1 		$400K Buy
15,103
+1,728
+13% +$61.5K 0.07% 235
2017
Q4 		$531K Buy
+13,375
New +$530K 0.07% 223

Other funds holding PCRX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Summit Trail Advisors's PCRX Position: Q2 2018 in Review

Summit Trail Advisors sold out of Pacira BioSciences (PCRX) in Q2 2018, closing a stake of 15,103 shares — an estimated $400K sold.

Summit Trail Advisors first reported a position in PCRX in Q4 2017 and held it in 2 quarters. The position peaked at $531K in Q4 2017. 156 funds tracked by Wall St. Rank hold PCRX as of Q2 2018.

  • Summit Trail Advisors reported no remaining Pacira BioSciences position as of Q2 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 15,103 Pacira BioSciences shares in Q2 2018, an estimated $400K.
  • Summit Trail Advisors first reported a position in Pacira BioSciences in Q4 2017 and held it in 2 quarters.
  • Summit Trail Advisors's Pacira BioSciences position peaked at $531K in Q4 2017.
  • 156 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2018.

Based on Summit Trail Advisors's 13F filing for Q2 2018, filed 10 Aug 2018.